

1 A new method of Non-Ultrasound Monitoring of Ovarian Stimulation
2 (NUMOS): Mission Possible! - a pilot study.

3
4 Iavor K. Vladimirov^{1,2}, Desislava Tacheva^{1,2}, Evan Gatev³, Magdalena Rangelova¹, Martin Vladimirov¹

5 ¹ SBALAGRM-SOFIA, Sofia, Bulgaria,

6 ² Sofia University "St.Kliment Ohridski", Cytology- Histology and Embryology., Sofia, Bulgaria,

7 ³ Bulgarian Academy of Science, Institute of Molecular Biology, Sofia, Bulgaria

8
9 Corresponding author: Iavor K. Vladimirov – vladimirov@ivf.bg, address:5B, Baku str., Sofia 1700, Bulgaria.

10
11 **Abstract:**

12 Purpose: This study aims to establish the viability of monitoring an appropriate and safe ovarian
13 stimulation without the use of ultrasound and serum hormone testing.

14 Method: As a primary marker for monitoring of the ovarian response, we used urinary estrone-3-
15 glucuronide (E1-3G) growth rate, which was self-measured by patients daily at home, with a portable
16 analyzer, during the stimulation. For an adequate ovarian response, an average daily rate of increase of
17 E1-3G was estimated to be within 25 - 77%. Ovulation trigger day was determined based on the length of
18 the menstrual cycle.

19 The study included 24 women. Inclusion criteria were age < 41 years and AMH >1 ng/mL. A progestin-
20 primed ovarian stimulation protocol (PPOS) with fixed doses of gonadotropins was used.

21 Results: The average female age was 32,9 years (± 4.4), BMI 22,7 kg/m² ($\pm 4,3$), AMH 3,7 ng/ml ($\pm 2,6$),
22 stimulation days 10,6 ($\pm 1,1$), collected oocytes 12,5 ($\pm 8,5$), MII oocytes 10,6 ($\pm 7,8$), fertilization rate 83,6%
23 ($\pm 22,5$), blastocyst 66,4% ($\pm 28,6$), good quality blastocysts 31,6% ($\pm 16,9$).

24 Absence of oocyte aspiration was found in one of the cases. There were no cases of OHSS and ovarian
25 stimulation cancellation.

26 Conclusion: This is the first pilot study to successfully apply a new markers for ovarian stimulation
27 monitoring.

28 **Keywords:** ovarian stimulation, monitoring, estrone-3-glucuronide, menstrual cycle length, progestin-
29 primed ovarian stimulation protocol.

30

31 **Introduction:**

32 Ovarian stimulation (OS) is defined as a pharmacological treatment with the intention of inducing the
33 development of more follicles in the ovaries, and consequently obtaining multiple oocytes by follicular
34 puncture (1). Control of ovarian stimulation (COS) is carried out through regular ultrasound
35 examinations and blood sampling to monitor the dynamics of hormones. The main reasons for applying
36 COS are to induce the maximum number of mature oocytes, thereby increasing the chance of live birth;
37 to determine the appropriate time to apply the so-called ovulation trigger for the final maturation of the
38 eggs and to prevent the risk of excessive ovarian response with ovarian hyperstimulation syndrome
39 (OHSS), a rare iatrogenic complication of COS (2). Frequent OS monitoring visits are costly and time-
40 consuming, as well as disrupting patients' daily rhythm. In a study done in different European countries,
41 21 to 36% of all patients claim that they consider it hard to find time off work to implement fertility
42 treatments. This is one of the main obstacle to seeking treatment (3).

43 To reduce the visits for ultrasound examinations, new methods are being developed to manage ovarian
44 stimulation during in vitro treatment. They depend upon examining estrone-3-glucuronide levels in
45 urine (4,5) and salivary hormone oestradiol and progesterone measurements (6).

46 Currently, two main stimulation approaches have been developed: Self-Operated Endovaginal
47 Telemonitoring /SOET/ (7) and Controlled Ovarian Stimulation Monitoring by Self-Determination of
48 Estrone-3-Glucuronide and Single Ultrasound (COSSESU). The implementation of these approaches is
49 carried out with the active participation of patients and with the assistance of some elements of
50 telemedicine (8). Some of the advantages that these two different approaches to ovarian stimulation
51 provide, are the reduction of: costs of regular ultrasound and hormone tests; stress gained due to
52 performing frequent blood tests in order to determine the values of different hormone levels in serum;
53 time wasted in frequent clinic visits and traveling; direct non-medical expenses related to the use of a
54 car, bus, train, hotel accommodation; food and risk of infection in situations similar to COVID-19.

55 The different approaches as described include elements of telemedicine. Even though many publications
56 have been made in regards to using telemedicine in cardiology, dermatology, diabetes, and general
57 practice, almost nothing has been reported regarding reproductive medicine. Interest has also increased
58 tremendously due to the recent COVID-19 pandemic. We support the notion that telemedicine has a
59 place in the treatment of infertility with the use of in vitro technologies (9).

60 This study aims to establish the viability of monitoring ovarian stimulation without the use of ultrasound
61 and serum hormone testing so that the stimulation is appropriate and safe. We called that new method
62 Non-Ultrasound Monitoring Ovarian Stimulation (NUMOS). Its main goal is to significantly reduce
63 patient visits during stimulation and their respective costs.

64

65 **Materials and Methods**

66 **Patient Selection Criteria**

67 All patients (n = 24) underwent COH and IVF/ICSI procedures at the clinic (Sofia IVF clinic, SBALAGRM-
68 SOFIA, Sofia, Bulgaria), during the period from November 2022 to January 2023. The study group of
69 patients applied the Freeze-all policy. Their embryos were cryopreserved for later FET without fresh ET.
70 All patients gave informed consent to participate in the program.

71 The study included 24 women with regular menstrual cycle (21-35 days) in 24 stimulated cycles.
72 Inclusion criteria were age < 41 years and AMH >1 ng/mL. Exclusion criteria: patients with a severe male
73 factor (spermatozoa ≤1 million/ml), and endometriosis.

74 **Method**

75 A progestin-primed ovarian stimulation protocol (PPOS) with fixed doses of gonadotropins was used.
76 The starting doses were determined based on a preliminary assessment of the ovarian reserve, carried
77 out in the previous 3 months.
78 Control of the adequacy of the ovarian response was based on monitoring the stimulation, as per the
79 dynamics in the urine E3G ratio by regular determination of the E3G in the urine independently by the
80 patients in home conditions. This was done with a small portable analyzer, which was easy to use and
81 takes a short time to read E3G in the sample. The patient then sends the obtained result to the
82 attending physician through a platform created for this purpose. A portable urine E3G analyzer and test
83 strips were given to patients free of charge and patients received no compensation for participation. For
84 an adequate ovarian response, an average daily rate of increase of E1-3G was estimated to be within 25
85 - 77% (10). In parallel, ultrasound examinations were performed, as the results of the study were not
86 used to monitor the stimulation but were intended to minimize the risk to patients and the patient
87 worries.

88 Criteria for determining the day for ovulation trigger and follicular puncture were based on the length of
89 the menstrual cycle. It was calculated on the base of average length of the natural menstrual cycle for
90 the three previous months, without the use of hormonal drugs for stimulation or contraceptives. We
91 assumed that the middle of the menstrual cycle +/- 1 day is the optimal day for follicular puncture.

92 Consider the following example of the new approach: with a 28-day menstrual cycle, the middle is the
93 14th day, respectively the ovulation trigger should be injected on the 12th day. If stimulation is started
94 on day 2, then the number of stimulated days will be 10 days. If the stimulation is started from the 3rd
95 day, then the number of stimulated days will be 9 days. In cycles longer than 30 days, stimulation lasts
96 longer, with the day of follicular puncture being the 16th (+/- 1) day of the menstrual cycle.

97 The deviation of one day was in accordance with the optimization of the work of the clinic related to the
98 end of the week. The days of gonadotropin stimulation have no bearing on determining the day of
99 follicular puncture.

100 A GnRH-agonist (Decapeptyl, Ferring) was used to trigger ovulation and was administered 34-36 hours
101 before the follicular puncture (Fig 1).

102 Oocytes were fertilized by ICSI and all embryos were cultivated to blastocyst phase, and frozen.

103

104 **Statistical analysis:**

105 The ranges were determined based on quantile analysis.

106 **Results:**

107 The average female age was 32,9 years (± 4.4), BMI 22,7 kg/m² ($\pm 4,3$), AMH 3,7 ng/ml ($\pm 2,6$), stimulation
108 days 10,6 ($\pm 1,1$), collected oocytes 12,5 ($\pm 8,5$), MII oocytes 10,6 ($\pm 7,8$), fertilization rate 83,6% ($\pm 22,5$),
109 blastocyst formation 66,4% ($\pm 28,6$), good quality blastocysts 31,6% ($\pm 16,9$).

110 Absence of oocyte aspiration was found in one of the cases. There were no cases of OHSS and ovarian
111 stimulation cancellation.

112

113 **Discussion:**

114 **Theoretical basis of the method.**

115 The success of the method is based on the application of criteria and methods that aim for the ovarian
116 response to be: 1) appropriate to the applied stimulation doses, 2) effective, i.e. aspiration of oocytes
117 sufficient in number and quality and 3) safe for the patients. The main factors on which the success of
118 ovarian stimulation and its effectiveness depend are as follows:

119 **Choice of stimulation protocol.**

120 The application of PPOS makes treatment more convenient for patients by replacing some subcutaneous
121 injections with oral medication.

122 The results of studies with different designs, different participant characteristics, and different
123 progestins have established high-quality evidence supporting the effectiveness of progestins in
124 obtaining similar numbers of oocytes with similar duration of stimulation and gonadotropin
125 consumption compared to other stimulation protocols (11).

126 On the other hand, Guan et al. (12) in a meta-analysis of randomized controlled trials found that the
127 number of oocytes retrieved, MII oocytes, and viable embryos was higher in PPOS protocols than in the

128 control protocol. Based on a systematic review and meta-analysis, other authors found more obtained
129 embryos in the PPOS protocol compared to standard stimulation protocols (13).

130 Next, the administration of progestins to inhibit ovulation with ovarian stimulation has been shown to
131 be effective and safe with a low risk of OHSS. With the progestin protocol, the strategy of Freeze-all
132 must be applied, in which case it is possible to apply a GnRH agonist as an ovulation trigger which
133 significantly reduces the risk of OHSS. (14)

134 The American Society for Reproductive Medicine states that the risk of OHSS is about 1-2% and can be
135 further reduced with the use of a GnRH agonist, triggering final oocyte maturation (15).

136 Ovulation triggering with a GnRH agonist almost completely eliminates the risk of OHSS without
137 affecting oocyte and embryo quality and is therefore the trigger of choice. (16).

138 The above-mentioned advantages of the PPOS protocol and the possibility of administration of GnRH
139 agonist as an ovulation trigger motivated our choice of the progestin protocol when applying the new
140 approach to control ovarian stimulation.

141 **Determining the stimulation doses.**

142 Various algorithms have been developed to determine the starting doses of gonadotropins. The
143 methods are based on preliminary determination of FSH and AMH levels, AFC, BMI, age, and history of
144 smoking (17, 18, 19, 20,21). These algorithms for determining the initial stimulating doses aim for
145 aspiration of 8-15 oocytes and eliminating the risk of OHSS in GnRH-agonist and antagonist protocols
146 and performing the so-called fresh ET. In our new approach to ovarian stimulation control, we apply a
147 PPOS protocol with mandatory embryo freezing. In this case, miscalculation of the stimulating doses and
148 the use of higher ones did not affect the LBR in thawed ET, in contrast to fresh ET. On the other hand,
149 when applying the Freeze-all strategy with a GnRH-agonist as an ovulation trigger, it would be desirable

150 to aim for the retrieval of between 15 and 20 oocytes, which represents a good balance between safety
151 and efficacy(22, 23).

152 **Monitoring the stimulation.**

153 Monitoring of the stimulation is based on the growth rate of E3G in the urine through its regular
154 determination, independently by the patients in home conditions. The method is based on a relatively
155 high correlation of estrone-3-glucuronide (E1-3G) urinary levels, which are a function of increasing
156 estradiol levels during stimulation (24,25,26,27). The correlation was also established using the specific
157 portable analyzer (4,10). Some components of the theoretical rationale developed by Vladimirov et al.
158 (8) for monitoring ovarian stimulation by determining urinary E3G were applied. An appropriate
159 response is identified with growth dynamics within established limits (28).

160 **Criteria for determining the day of follicular puncture.**

161 Our proposed new algorithm for determining the day follicular puncture is based on a thorough analysis
162 of various scientific facts and regularities. We examined the relationship between the size of the
163 follicles, the duration of the stimulation, and the length of the menstrual cycle, as well as the maturity of
164 the oocytes, the quality of the embryos, and the success rate of the treatment.

165 A major method for predicting the possibility of aspiration of mature oocytes is the size of the follicles
166 during ovarian stimulation. It is known that metaphase II (mature) oocytes can be aspirated from
167 follicles of various sizes. In the literature, data on the ideal follicle size that determines the exact
168 moment to apply the ovulation trigger are conflicting. No universally accepted follicle size threshold has
169 been established to predict the presence of good competent oocytes. Overall, there is evidence that
170 follicles with an average diameter between 16 and 22 mm are those most likely to contain MII oocytes,
171 whereas small follicles rarely can generate MII oocytes. The frequency of mature oocytes increases with
172 follicle size (329), however, in both relatively small and very large follicles, non-metaphase II oocytes can

173 be aspirated. Mature oocytes are often aspirated from follicles larger than 16 mm in size. A greater
174 number of immature oocytes are found in follicles smaller than 12 mm, and some authors recommend
175 that such follicles should not be aspirated (30,31). Other authors found that mature oocytes can be
176 aspirated from follicles with a smaller diameter, respectively between 11 to 14 mm (32,33,34).
177 Regarding the size of the follicles and the development of the embryos after fertilization, no relationship
178 has been established because the results are contradictory (35,36). This suggests that the optimal follicle
179 size may be population-specific.

180 In other studies, the authors found that in oocytes obtained from smaller follicles, the degree of
181 polyspermy was higher after fertilization by conventional IVF, as well as a higher degree of
182 fragmentation was observed, associated with a lower pregnancy rate (30). These effects may be due to
183 reduced oocyte competence or due to safeguards against the entry of more than one spermatozoon and
184 development during subsequent cleavage stages. Other authors did not confirm differences in oocyte
185 maturation rate (35) or fertilization rate between small and large follicles. A mature oocyte can be
186 obtained from a follicle measuring between 12 and 24 mm. Oocytes can be in metaphase II
187 development, despite being derived from small follicles (0.3–0.9 mL volume), showing similar
188 fertilization capacity and rate of blastocyst formation compared to oocytes of larger follicles (1-6 mL and
189 >6 mL) (37). Some publications have demonstrated reduced fertilization rate and developmental
190 competence of oocytes derived from very large (>23 mm) follicles, indicating the adverse effects of
191 prolonged stimulation (38,39).

192 The facts presented above and our analysis give us reasons to believe that the size of the follicle from
193 which a mature oocyte with normal characteristics can be aspirated varies widely. On the other hand,
194 the main ultrasound criteria for determining an ovulation trigger, namely the presence of at least 3
195 follicles larger than 17 mm, also allows for a broader interpretation of the optimal day for follicular
196 puncture.

197 **The question arises, does the day of follicular puncture depend on the duration of stimulation?**

198 A number of authors have found that in the different protocols (long, antagonist or flare stimulation
199 protocol), the duration of ovarian stimulation has no negative effect on the success rate in IVF/ICSI
200 procedure (40). Optimal ovarian response and pregnancy outcome is associated with stimulation
201 duration between 9 -12 days (41).

202 Several authors have sought an answer to the question, whether changing the day for follicular puncture
203 by one day from the optimal one (determined by ultrasound), has a negative effect on the quality of
204 aspirated oocytes, respectively embryos and delivery rate. The purpose of the studies is to avoid
205 performing follicular punctures on the weekend, and the results are related to determining the success
206 rate based on fresh embryo transfer. Ben-Chetrit et al. (42) found that performing the follicular
207 puncture a day earlier or later had no negative effect on the success rate using a GnRH-analogues
208 protocol. Other authors have found that delaying hCG administration by 1 or 2 days does not worsen
209 results in regard to the agonist protocol.

210 Another study has found that in patients with fixed days of stimulation in a long protocol, success rates
211 were similar to those who had conventional ovarian stimulation monitoring (43). Similar results and
212 conclusions also have been reported by authors applying an antagonist protocol in ovarian stimulation.
213 Tremellen et al. (44) report that the early implementation of follicular puncture by 1 day from the
214 optimum, leads to a decrease in the number of aspirated oocytes and created embryos. Delaying
215 puncture by 1 day from optimal results in a non-significant increase in the number of oocytes collected
216 and embryos created. However, the implementation of follicular puncture with the deviation of a day
217 from the optimal one has no significant effect on the success rate based on live birth rates. The authors
218 report that in a retrospective analysis of a large, randomized clinical trial (Engage) a one-day delay in

219 HCG as an ovulation trigger does not negatively affect either the number of oocytes aspirated, or the
220 pregnancy rate (45).

221 In support of the above studies (46,47,48,49) and the results of a meta-analysis of seven RCTs (50), the
222 authors suggest that a delay in follicular puncture within 1-2 days when using a GnRH-antagonist
223 protocol may result to aspiration of more mature oocytes without having an adverse effect on
224 implantation and ongoing pregnancy rate. Mirzachi et al. (16) in their systematic review, reported that:
225 moderate-quality evidence indicates that in freeze-all cycles, a moderate delay of 2–3 days in ovulation
226 triggering may result in the retrieval of an increased number of mature oocytes without impairing the
227 pregnancy rate. According to the authors, ovarian stimulation for frozen cycles is different in many
228 aspects from conventional stimulation for fresh IVF cycles.

229 It is clear from the above that the duration of ovarian stimulation with gonadotropins can be within
230 relatively wide limits, without having a negative effect on the quality of the oocytes, respectively
231 pregnancy and live births.

232 For this reason, we looked for another approach and the use of other parameters to determine the
233 ovulation trigger day and the follicular puncture day, respectively.

234 Already at the dawn of IVF technologies, a solution was sought through the so-called programmed
235 oocyte retrieval to find a method that does not use US monitoring of ovarian stimulation. The authors
236 used a predetermined day to apply an ovulation trigger without regard to the ovarian response. The
237 authors report that this ovarian stimulation approach was effective in the treatment of infertility
238 through the IVF procedure and was associated with significant practical and economic benefits (51,
239 52,53).

240 We hypothesized that the length of the menstrual cycle could be used to determine the duration of
241 ovarian stimulation and that this would not negatively affect the success of the IVF procedure. It is

242 known that the length of the menstrual cycle has a relationship with the aging of the ovary and its
243 reserve (51). As ovarian function declines, the follicular phase is shortened, which is associated with
244 lower AMH and AFC and poor IVF outcomes (16). On the other hand, menstrual cycle length has
245 prognostic value for ovarian response in OS (54,55,56).

246 A study by Zhao et al. (57) remains in support of the thesis that the length of the menstrual cycle can be
247 successfully applied as a marker to determine the day of follicular puncture. The authors determine the
248 optimal day for triggering ovulation, based on determining the length of the follicular phase of the
249 menstrual cycle. They define it as the difference between the length of the menstrual cycle and the
250 length of the luteal phase, which is 14 days. 6,110 women with regular menstrual cycles were included
251 in the study. From the analysis of the different groups, it can be seen that the days of stimulation vary
252 between 8-12 days. A significant difference was found in the number of oocytes, fertilizations, embryos,
253 and embryos of good quality in the different groups of patients, but this was not observed in
254 comparisons based on pregnancies and births. The Q3 group, which has the best success rates, has an
255 OS/FP (ovarian stimulation/follicular phase) ratio of 0.67-0.77. After analysis, it is evident that with a
256 regular 28-day cycle, in the Q3 group, stimulation varying from 9 to 11 can be included, which are
257 relatively wide limits.

258 Ours is the first pilot study to successfully apply a new approach to ovarian stimulation monitoring
259 without the use of ultrasound and hormone analysis. This new method of monitoring and controlling
260 ovarian stimulation based on other criteria such as the dynamics in the levels of E1-3G in urine and the
261 length of the menstrual cycle. The in-depth analysis of the results of the studies, as well as our
262 experience in using E1-3G in urine as a marker for the effectiveness of ovarian stimulation, motivated us
263 to develop and successfully implement this new approach for monitoring the stimulation. The method
264 can successfully replace the classical approach of monitoring stimulation through regular ultrasound
265 examinations and analysis of serum hormone levels.

266 **Limitations:**

267 This study has some limitations. First, it is necessary to apply the method to a larger group of patients.

268 Next, it is also necessary address the question, is this approach applicable only to the Freeze-all strategy

269 or is it also possible to apply it with protocols that allow the implementation of fresh ET?

270 **Conclusion:**

271 This is a new approach for stimulation monitoring and does not exclude the use of standard methods. Its

272 main goal is reducing patient visits during stimulation, respectively direct and indirect costs in IVF

273 treatment.

274 In recent decades, we have witnessed the introduction of new technologies into assisted reproduction.

275 The entry of artificial intelligence and telemedicine is already a fact. Established perceptions and

276 approaches about how to control ovarian stimulation are constantly evolving. The development of new

277 stimulation protocols and different strategies enables a look into a new era of IVF in the 21st century.

278 The new ovarian stimulation monitoring method developed and successfully implemented by us is part

279 of this future. A two visits IVF treatment (TV/IVF) approach is now a reality, through which we will

280 reduce the direct and indirect costs of infertility treatment. The current technology allows it!

281 **Data Availability Statement**

282 The raw data supporting the conclusions of this article will be made available by the authors, without

283 undue reservation.

284 **Ethics Statement**

285 The studies involving human participants were reviewed and approved by the Ethics Committee of the
286 SBALAGRM-SOFIA hospital. Informed consent for participation was written patients did not receive any
287 compensation for participation.

288 **Data sharing statement:** Consent to share data was not obtained thus individual patient data will not be
289 shared.

290 **Author Contributions:**

291 IKV: Design, conception, analysis and interpretation of data, drafting of article, writing - review &
292 editing, supervision. DT: Design, drafting of article, funding acquisition. MR: Acquisition of data, design.
293 IG: Analysis and interpretation of data, writing - review & editing, visualization. MV: Conception, writing
294 - review & editing, visualization. All authors approved the final manuscript. All authors contributed to
295 the article and approved the submitted version.

296 **Funding** -NA

297 **Conflict of Interest**

298 The authors declare that the research was conducted in the absence of any commercial or financial
299 relationships that could be construed as a potential conflict of interest.

300 **Acknowledgments:**

301 The authors would like to thank all the medical staff in the SBALAGRM-SOFIA for their assistance in data
302 collection.

303

304 **References:**

- 305 1. Le KD, Vuong LN, Ho TM, Dang VQ, Pham TD, Pham CT, et al. A cost-effectiveness analysis of
306 freeze only or fresh embryo transfer in IVF of non-PCOS women. *Human Reproduction*.
307 2018;33(10):1907-1914
- 308 2. Wu AK, Elliott P, Katz PP, Smith JF. Time costs of fertility care: The hidden hardship of building a
309 family. *Fertility and Sterility*. 2013; 99:2025-2030. DOI: 10.1016/j.fertnstert.2013.01.145
- 310 3. Kelly J, Hughes CM, Harrison RF. The hidden costs of IVF. *Irish Medical Journal*. 2006; 99:142-143
- 311 4. Vladimirov I, Martin V, T Desislava T. Urine estrone–3-glucuronide (E3G) assay: Is there any
312 place during ovarian stimulation for IVF cycles? *Human Reproduction*, Volume 36, Issue Supplement_1,
313 deab130.669, 2021
- 314 5. Hart RJ, D’Hooghe T, Dancet EAF, Aurell R, Lunenfeld B, Orvieto R, et al. Self-monitoring of
315 urinary hormones in combination with telemedicine - a timely review and opinion piece in medically
316 assisted reproduction. *Reproductive Sciences*. 2021; 29:1-14. DOI: 10.1007/s43032-021-00754-5
- 317 6. Sakkas D, Howles CML, Atkinson L, Borini A, Bosch EA, Bryce C, et al. A multi-Centre
318 international study of salivary hormone Oestradiol and progesterone measurements in ART monitoring.
319 *Reproductive Biomedicine Online*. 2020; 42:421-428
- 320 7. Gerris J, Annick DA, Dhont N, Frank VF, Madoc B, Magaly BM, et al. Self-operated Endovaginal
321 Telemonitoring versus traditional monitoring of ovarian stimulation in assisted reproduction: An RCT.
322 *Human Reproduction*. 2014; 29:1941-1948. DOI: 10.1093/humrep/deu168
- 323 8. Vladimirov IK, Vladimirov M, Tacheva D. A new protocol for controlled ovarian stimulation
324 monitoring by self-determination of Estrone-3-glucuronide and single ultrasound (COSSESU). *Open*
325 *journal of Obstetrics and Gynecology*. 2021; 11:1217-1228

- 326 9. Berg WT, Goldstein M, Melnick AP, Rosenwaks Z. Clinical implications of telemedicine for
327 providers and patients. *Fertility and Sterility*. 2020;114(6):1129-1134. DOI:
328 10.1016/j.fertnstert.2020.10.048.
- 329 10. Vladimirov I K, Tacheva D, Gatev E, Rangelov M and Vladimirov M. Viability of home monitoring
330 of estrone-3-glucuronide (E1-3G) urine levels in controlled ovarian stimulation: A pilot study. *Human*
331 *Reproduction*, Volume 38, Issue Supplement_1, June 2023, dead093.932,
332 <https://doi.org/10.1093/humrep/dead093.93230>.
- 333 11. Ata B, Capuzzo M, Turkgeldi E, Yildiz S, La Marca A. Progestins for pituitary suppression during
334 ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses. *Hum*
335 *Reprod Update*. 2021 Jan 4;27(1):48-66. doi: 10.1093/humupd/dmaa040.
- 336 12. Guan S, Feng Y, Huang Y and Huang J. Progestin-Primed Ovarian Stimulation Protocol for
337 Patients in Assisted Reproductive Technology: A Meta-Analysis of Randomized Controlled Trials. *Front*
338 *Endocrinol (Lausanne)*. 2021 Aug 31;12: 702558. doi: 10.3389/fendo.2021.702558. eCollection 2021.
- 339 13. Cui L, Lin Y, Wang F, Chen C. Effectiveness of progesterone-primed ovarian stimulation in
340 assisted reproductive technology: a systematic review and meta-analysis. *Arch Gynecol Obstet*. 2021
341 Mar;303(3):615-630. doi: 10.1007/s00404-020-05939-y. Epub 2021 Jan 12.
- 342 14. La Marca A and Capuzzo M. Use of progestins to inhibit spontaneous ovulation during ovarian
343 stimulation: the beginning of a new era? *Reprod Biomed Online*. 2019 Aug;39(2):321-331. doi:
344 10.1016/j.rbmo.2019.03.212. Epub 2019 Mar 29.
- 345 15. Practice Committee of the American Society for Reproductive Medicine and Practice Committee
346 of the Society for Assisted Reproductive Technology. Repetitive oocyte donation: a committee opinion.
347 *Fertil Steril* 2014; 102:964–966.

- 348 16. Mizrachi Y, Horowitz E, Farhi J, Raziel A and Weissman A. Ovarian stimulation for freeze-all IVF
349 cycles: a systematic review. *Human Reproduction Update*, Vol.26, No.1, pp. 119–136, 2020.
- 350 17. Popovic-Todorovic B, Loft A, Bredkjær HE, Bangsbøll S, Nielsen IK, Andersen AN. A prospective
351 randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors
352 versus a ‘standard’ dose of 150 IU/day in ‘standard’ patients undergoing IVF/ICSI treatment. *Human*
353 *Reprod.* 2003;18(11):2275–2282.
- 354 18. Popovic-Todorovic B, Loft A, Lindhard A, Bangsbøll S, Andersson AM, Andersen AN. A
355 prospective study of predictive factors of ovarian response in ‘standard’ IVF/ICSI patients treated with
356 recombinant FSH. A suggestion for a recombinant FSH dosage normogram. *Human Reprod.*
357 2003;18(4):781–787.
- 358 19. Howles CM, Saunders H, Alam V, Engrand P. Predictive factors and a corresponding treatment
359 algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle
360 stimulating hormone (Follitropin alfa) during assisted reproduction technology (ART) procedures. An
361 analysis of 1378 patients. *Curr Med Res Opin.* 2006;22(5):907–918.
- 362 20. Olivennes F, Howles CM, Borini A, et al. Individualizing FSH dose for assisted reproduction using
363 a novel algorithm: the CONSORT study. *Reprod Biomed Online.* 2009;18(2):195–204.
- 364 21. Yovich JL, Alsbjerg B, Conceicao JL, Hinchliffe PM, Keane KN. PIVET rFSH dosing algorithms for
365 individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and
366 avoidance of ovarian hyperstimulation syndrome. *Drug Des Devel Ther.* 2016 Aug 10;10: 2561-73. doi:
367 10.2147/DDDT.S104104. eCollection 2016.
- 368 22. Gerber RS, Fazzari M, Kappy M, Cohen A, Galperin S, Lieman H, et al.. Differential Impact of
369 Controlled Ovarian Hyperstimulation on Live Birth Rate in Fresh Versus Frozen Embryo Transfer Cycles: A

- 370 Society for Assisted Reproductive Technology Clinic Outcome System Study. *Fertil Steril* (2020)
371 114:1225–31.
- 372 23. Munch EM, Sparks AE, Zimmerman MB, Van Voorhis BJ, Duran EH. High FSH dosing is associated
373 with reduced live birth rate in fresh but not subsequent frozen embryo transfers. *Hum Reprod* 2017;32:
374 1402–1409.
- 375 24. Rapi S, Fuzzi B, Mannelli M, Pratesi S, Criscuoli L, Pellegrini S, et al. Estrone 3-glucuronide
376 chemiluminescence immunoassay (LIA) and 17beta estradiol radioimmunoassay (RIA) in the monitoring
377 of superovulation for in vitro fertilization (IVF): correlation with follicular parameters and oocyte
378 maturity. *Acta Eur Fertil*. 1992;23(2):63–8
- 379 25. Catalan R, Castellanos JM, Palomino T, Senti M, Antolin M, Galard RM. Correlation between
380 plasma estradiol and estrone3-glucuronide in urine during the monitoring of ovarian induction
381 therapy. *Int J Fertil*. 1989;34(4):271–5.
- 382 26. Alper MM, Halvorson L, Lasley B, Mortola J. Relationship between urinary estrone conjugates as
383 measured by enzyme immunoassay and serum estradiol in women receiving gonadotropins for in vitro
384 fertilization. *J Assist Reprod Genet*. 1994;11(8):405–8.
- 385 27. Gary S. Nakhuda, Ning Li, Zheng Yang, Sylvia Kang. At-home urine estrone-3-glucuronide
386 quantification predicts oocyte retrieval outcomes comparably to serum estradiol. *FS Rep* 2023 Jan
387 28;4(1):43-48.
- 388 28. Simonetti S, Veeck LL, Jones HW Jr. Correlation of follicular fluid volume with oocyte morphology
389 from follicles stimulated by human menopausal gonadotropin. *Fertil Steril*. 1985;44(2):177–80.
- 390 29. Bergh C, Broden H, Lundin K, Hamberger L. Comparison of fertilization, cleavage and pregnancy
391 rates of oocytes from large and small follicles. *Hum Reprod*. 1998;13(7):1912–5.

- 392 30. Rosen MP, Shen S, Dobson AT, Rinaudo PF, McCulloch CE, Cedars MI. A quantitative assessment
393 of follicle size on oocyte developmental competence. *Fertil Steril*. 2008;90(3):684–90.
- 394 31. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-stimulating
395 hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. *Fertil Steril*.
396 1989;51(4):651–4.
- 397 32. Mehri S, Levi Setti PE, Greco K, Sakkas D, Martinez G, Patrizio P. Correlation between follicular
398 diameters and flushing versus no flushing on oocyte maturity, fertilization rate and embryo quality. *J*
399 *Assist Reprod Genet*. 2014;31(1):73–7.
- 400 33. Akbariasbagh F, Lorzadeh N, Azmoodeh A, Ghaseminejad A, Mohamadpoor J, Kazemirad S.
401 Association among diameter and volume of follicles, oocyte maturity, and competence in
402 intracytoplasmic sperm injection cycles. *Minerva Ginecol*. 2015;67:397–403.
- 403 34. Salha O, Nugent D, Dada T, Kaufmann S, Levett S, Jenner L, Lui S, Sharma V. The relationship
404 between follicular fluid aspirate volume and oocyte maturity in in-vitro fertilization cycles. *Hum Reprod*.
405 1998;13:1901–16.
- 406 35. Nogueira D, Friedler S, Schachter M, Raziel A, Ron-El R, Smitz J. Oocyte maturity and
407 preimplantation development in relation to follicle diameter in gonadotropin-releasing hormone agonist
408 or antagonist treatments. *Fertil Steril*. 2006;85:578–83.
- 409 36. Haines CJ, Emes AL. The relationship between follicle diameter, fertilization rate, and
410 microscopic embryo quality. *Fertil Steril*. 1991;55:205–7.
- 411 37. Raine-Fenning N, Deb S, Jayaprakasan K, Clewes J, Hopkisson J, Campbell B. Timing of oocyte
412 maturation and egg collection during controlled ovarian stimulation: a randomized controlled trial
413 evaluating manual and automated measurements of follicle diameter. *Fertil Steril*. 2010;94:184–8.

- 414 38. Ectors FJ, Vanderzwalmen P, Van Hoeck J, Nijs M, Verhaegen G, Delvigne A, Schoysman R, Leroy
415 F. Relationship of human follicular diameter with oocyte fertilization and development after in-vitro
416 fertilization or intracytoplasmic sperm injection. *Hum Reprod.* 1997;12:2002–5.
- 417 39. Wertheimer A, Nagar R, Oron G, Meizner I, Fisch B, Ben-Haroush A. Fertility treatment outcomes
418 after follicle tracking with standard 2-dimensional sonography versus 3-dimensional sonography-based
419 automated volume count: prospective study. *J Ultrasound Med.* 2018;37(4):859–66.
- 420 40. Purandare N, Emerson G, Kirkham C, Harrity C, Walsh D, Mocanu E. The duration of
421 gonadotropin stimulation does not alter the clinical pregnancy rate in IVF or ICSI cycles. *Ir J Med Sci*
422 (2017) 186:653–657.
- 423 41. Sarkar P, Ying L, Plosker S, Mayer J, Ying Y, Imudia AN. Duration of ovarian stimulation is
424 predictive of in-vitro fertilization outcomes. *Minerva Ginecol.* 2019 Dec;71(6):419-426. doi:
425 10.23736/S0026-4784.19.04455-1. Epub 2019 Nov 13.
- 426 42. Ben-Chetrit, A., Senoz, S., Greenblatt, E.M., 1997. In vitro fertilization programmed for weekday-
427 only oocyte harvest: analysis of outcome based on actual retrieval day. *J. Assist. Reprod. Genet.* 14, 26–
428 31.
- 429 43. Nakagawa, K., Yamano, S., Senuma, M., Myogo, K., Yamazaki, J., Aono, T., 1997. Avoidance of
430 oocyte retrieval on the weekend through the use of scheduled ovarian hyperstimulation for in vitro
431 fertilization and embryo transfer. *Fertil. Steril.* 68, 787–79.
- 432 44. Tremellen, K.P., Lane, M., 2010. Avoidance of weekend oocyte retrievals during GnRH antagonist
433 treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth
434 outcomes. *Hum. Reprod.* 25, 1219–1224.

- 435 45. Levy MJ, Ledger W, Kolibianakis EM, Ijzerman-Boon PC, Gordon K. It is possible to reduce the
436 incidence of weekend oocyte retrievals in GnRH antagonist protocols? *Reprod Biomed Online*. 2013
437 Jan;26(1):50-8. doi: 10.1016/j.rbmo.2012.09.014. Epub 2012 Sep 26.
- 438 46. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Prolongation
439 of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles
440 stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone
441 antagonists. *Fertil Steril* 2004;82:102–107.
- 442 47. Kolibianakis EM, Bourgain C, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC,
443 Devroey P. Prolongation of follicular phase by delaying hCG administration results in a higher incidence
444 of endometrial advancement on the day of oocyte retrieval in GnRH antagonist cycles. *Hum Reprod*
445 2005;20:2453–2456.
- 446 48. Morley L, Tang T, Yasmin E, Hamzeh R, Rutherford AJ, Balen AH. Timing of human chorionic
447 gonadotrophin (hCG) hormone administration in IVF protocols using GnRH antagonists: a randomized
448 controlled trial. *Hum Fertil (Camb)* 2012;15:134–139.
- 449 49. Levy MJ, Ledger W, Kolibianakis EM, Ijzerman-Boon PC, Gordon K. Is it possible to reduce the
450 incidence of weekend oocyte retrievals in GnRH antagonist protocols? *Reprod Biomed Online*
451 2013;26:50–58.
- 452 50. Chen Y, Zhang Y, Hu M, Liu X, Qi H. Timing of human chorionic gonadotropin (hCG) hormone
453 administration in IVF/ICSI protocols using GnRH agonist or antagonists: a systematic review and
454 metaanalysis. *Gynecol Endocrinol* 2014;30:431–437.

- 455 51. Vassena R, Vidal R, Coll O, Vernaeve V. Menstrual Cycle Length in Reproductive Age Women Is
456 an Indicator of Oocyte Quality and a Candidate Marker of Ovarian Reserve. *Eur J Obstet Gynecol Reprod*
457 *Biol* (2014) 177:130–4. doi: 10.1016/j.ejogrb.2014.03.027
- 458 52 Braude P R, Bright M V, Douglas C P, Milton P J, Robinson R E, Williamson J G, Hutchison J. A
459 regimen for obtaining mature human oocytes from donors for research into human fertilization in vitro.
460 *Fertil Steril*. 1984 Jul;42(1):34-8.
- 461 53. Frydman R, Rainhorn J D, Forman R, Belaisch-Allart J, Fernandez H, Lassalle B, Testart J.
462 Programmed oocyte retrieval during routine laparoscopy and embryo cryopreservation for later transfer
463 *Am J Obstet Gynecol*. 1986 Jul;155(1):112-7. doi: 10.1016/0002-9378(86)90091-8.
- 464 5. Frydman R, Forman R, Rainhorn J D, Belaisch-Allart J, Hazout A, Testart J. A new approach to
465 follicular stimulation for in vitro fertilization: programmed oocyte retrieval *Fertil Steril*. 1986
466 Oct;46(4):657-62. doi: 10.1016/s0015-0282(16)49644-5.
- 467 54. Gizzo S, Andrisani A, Noventa M, Quaranta M, Esposito F, Armanini D, et al. . Menstrual Cycle
468 Length: A Surrogate Measure of Reproductive Health Capable of Improving the Accuracy of
469 Biochemical/Sonographical Ovarian Reserve Test in Estimating the Reproductive Chances of Women
470 Referred to ART. *Reprod Biol Endocrinol* (2015) 13:28. doi: 10.1186/s12958-015-0024
- 471 55. Younis JS, Iskander R, Fauser BCJM, Izhaki I. Does an Association Exist Between Menstrual Cycle
472 Length Within the Normal Range and Ovarian Reserve Biomarkers During the Reproductive Years? A
473 Systematic Review and Meta-Analysis. *Hum Reprod Update* (2020) 26:904–28. doi:
474 10.1093/humupd/dmaa013

475 56. Oehninger S, Nelson SM, Verweij P, Stegmann BJ. Predictive Factors for Ovarian Response in a
476 Corifollitropin Alfa/GnRH Antagonist Protocol for Controlled Ovarian Stimulation in IVF/ICSI Cycles.
477 *Reprod Biol Endocrinol* (2015) 13:117. doi: 10.1186/s12958-015-0113-1.

478 57. Xinyang Zhao, Xu Zhang, Shanshan Wu, Jichun Tan. Association Between the Ratio of Ovarian
479 Stimulation Duration to Original Follicular Phase Length and In Vitro Fertilization Outcomes: A Novel
480 Index to Optimise Clinical Trigger Time *Front Endocrinol (Lausanne)* . 2022 Jul 25;13:862500. doi:
481 10.3389/fendo.2022.862500. eCollection 2022.

482

483

484

FIGURE 1




Fig. 1. Non-Ultrasound Monitoring of Ovarian Stimulation (NUMOS)

medRxiv preprint doi: <https://doi.org/10.1101/2023.10.26.23297609>; this version posted October 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).